Positive Trial Results For Cell Genesys
Last week, Cell Genesys Inc. (CEGE) reported positive trial data for its prostate cancer treatment GVAX sending the stock price soaring $1.42 to close at $6.86.
posted by FC Market News at 3:45 PM
0 Comments:
Post a Comment
<< Home